NYSE:DPLO - Diplomat Pharmacy Stock Price, Price Target & More

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings results on Monday, May, 7th. The company reported $0.20 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.21 by $0.01. The business earned $1.34 billion during the quarter, compared to the consensus estimate of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The firm's revenue was up 24.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.19 earnings per share. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy issued an update on its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share (EPS) guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.

11 brokerages have issued 1-year price targets for Diplomat Pharmacy's stock. Their forecasts range from $18.00 to $35.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $26.90 in the next year. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Ratings for Diplomat Pharmacy.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), Petmed Express (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

News coverage about DPLO stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.15 on Accern's scale. They also assigned media coverage about the company an impact score of 46.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Columbia Partners L L C Investment Management (0.10%), Campbell & CO Investment Adviser LLC (0.01%), Xact Kapitalforvaltning AB (0.01%) and Bank of Montreal Can (0.01%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Campbell & CO Investment Adviser LLC and Xact Kapitalforvaltning AB. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $26.10.

Diplomat Pharmacy has a market capitalization of $1.95 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]